# Protagonist Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protagonist-therapeutics

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.protagonist-inc.com
- Total disclosed funding: $41M
- Latest round: Series C (Jul 10, 2015)
- Investors on record: 9

## About

Protagonist Therapeutics, Inc. is a biotechnology company focused on peptide drug discovery and development, delivering innovative therapies for diseases with significant unmet medical needs.Founded in 2001 and headquartered in Newark, US, Protagonist Therapeutics, Inc. specializes in peptide-based therapies. The company was co-founded by Aaron Rasmussen. As of December 2020, Protagonist raised USD 115.00 mn in a Private Placement/Follow on financing, total funds raised amounting to USD 115.00 mn through 14 deals.Protagonist Therapeutics, Inc. specializes in peptide drug discovery and development, focusing on innovative therapies for rare and prevalent diseases with limited treatment options. Its investigational peptide-based therapies are advancing through clinical studies aimed at diverse patient demographics, particularly addressing the needs of the aging population in North America and Europe.In the most recent year of 2024, Protagonist Therapeutics generated revenue of USD 434.43 mn with an EBITDA of USD 253.67 mn, primarily through collaborations and partnerships with pharmaceutical companies and research institutions.Protagonist Therapeutics plans to leverage its recent funding to support the advancement of its peptide-based therapies into new therapeutic markets. The company is focused on launching new products in 2024, expanding its reach within North America and Europe, and plans to utilize the proceeds from the USD 115.00 mn raised in December 2020 to enhance its research and development efforts as well as regulatory strategies.

## Funding rounds

- Series C, Jul 10, 2015, $18M — Canaan Partners, Starfish Ventures, Lilly Ventures, Johnson & Johnson Innovation, Adage Capital Management, Foresite Capital, RA Capital Management, Pharmstandard International S.A.
- Series B, Jun 4, 2013, $14M — Starfish Ventures, Lilly Ventures, Johnson & Johnson Innovation
- Series A, Sep 19, 2006, $9M — Starfish Ventures, Lilly Ventures, QIC

## Investors

- Starfish Ventures (https://capitalatlas.ai/funds/starfish-ventures) — Series A, Series B, Series C
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A, Series B, Series C
- QIC (https://capitalatlas.ai/funds/qic) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C
- Adage Capital Management — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Pharmstandard International S.A. — Series C